809 related articles for article (PubMed ID: 32641091)
1. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
Liu X; Chen H; Shang Y; Zhu H; Chen G; Chen Y; Liu S; Zhou Y; Huang M; Hong Z; Xia J
Trials; 2020 Jul; 21(1):622. PubMed ID: 32641091
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
4. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
6. Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.
Dalili N; Kashefizadeh A; Nafar M; Poorrezagholi F; Firouzan A; Samadian F; Samavat S; Ziaie S; Fatemizadeh S
Trials; 2020 Jun; 21(1):489. PubMed ID: 32503620
[TBL] [Abstract][Full Text] [Related]
7. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Baralić K; Jorgovanović D; Živančević K; Antonijević Miljaković E; Antonijević B; Buha Djordjevic A; Ćurčić M; Đukić-Ćosić D
Toxicol Appl Pharmacol; 2020 Nov; 406():115237. PubMed ID: 32920000
[TBL] [Abstract][Full Text] [Related]
8. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
[TBL] [Abstract][Full Text] [Related]
9. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
[TBL] [Abstract][Full Text] [Related]
10. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
12. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
[TBL] [Abstract][Full Text] [Related]
13. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
15. Treating COVID-19 with Chloroquine.
Huang M; Tang T; Pang P; Li M; Ma R; Lu J; Shu J; You Y; Chen B; Liang J; Hong Z; Chen H; Kong L; Qin D; Pei D; Xia J; Jiang S; Shan H
J Mol Cell Biol; 2020 May; 12(4):322-325. PubMed ID: 32236562
[No Abstract] [Full Text] [Related]
16. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
Levy C; Lassailly G; Parmentier E; Duburcq T; Mathurin P; Poissy J
Am J Gastroenterol; 2020 Oct; 115(10):1716-1718. PubMed ID: 32858566
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.
Zheng F; Zhou Y; Zhou Z; Ye F; Huang B; Huang Y; Ma J; Zuo Q; Tan X; Xie J; Niu P; Wang W; Xu Y; Peng F; Zhou N; Cai C; Tang W; Xiao X; Li Y; Zhou Z; Jiang Y; Xie Y; Tan W; Gong G
Int J Infect Dis; 2020 Oct; 99():84-91. PubMed ID: 32758689
[TBL] [Abstract][Full Text] [Related]
18. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
Bhattacharyya A; Kumar S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bansal S; Avti P; Hazarika M; Sharma S; Mahendru D; Prakash A; Medhi B
Indian J Pharmacol; 2020; 52(4):313-323. PubMed ID: 33078733
[TBL] [Abstract][Full Text] [Related]
20. A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial.
Abayomi A; Osibogun A; Ezechi O; Wright K; Ola B; Ojo O; Kuyinu Y; Zamba E; Abdur-Razzaq H; Erinoso OA; Anya SE
Trials; 2021 Dec; 22(1):869. PubMed ID: 34863267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
